UBS analysts maintained a Buy rating for Alvotech SA (NASDAQ:ALVO) with a steady price target of $18.00, representing a 41% ...
The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback